KRAS (Kirsten Ras protein) was found to be the most common locus for somatic gain-of-function mutations in patients with pancreatic cancer, accounting for about 95% (Morris et al., 2010; Eibl and Rozengurt, 2019). Here, KRAS is linked to familial pancreatic carcinoma.